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Abstract
The association between non-alcoholic fatty liver disease (NAFLD) and diabetic kidney disease assessed using either albuminuria or
proteinuria remains controversial. This study aimed to investigate the association between hepatic steatosis or fibrosis and
albuminuria or proteinuria in Korean patients with type 2 diabetes mellitus (T2D).
We enrolled 1108 patients with T2D and categorized as 3 groups; non-proteinuria (NP), isolated non-albumin proteinuria (iNAP),
and albuminuria. Urinary albumin and protein levels were assessed as urinary albumin-to-creatinine ratio (uACR) and urinary protein-
to-creatinine ratio (uPCR), respectively. Hepatic steatosis and fibrotic burden were assessed using the NAFLD liver fat score,
Fibrosis-4 calculator (FIB-4) index, and NAFLD fibrosis score (NFS).
The prevalence of significant steatosis was similar among groups (NP: 74.6% vs iNAP: 70.3% vs albuminuria: 79.9%, P= .085).
The prevalence of significant fibrosis was significantly higher in the iNAP (18.7%) and albuminuria (16.5%) groups than in the NP
group (9.5%, P= .001). Both uPCR and uACR showed a correlation with NFS (uPCR: r=0.123, P< .001; uACR: r=0.064, P= .033).
In multivariate logistic regression analysis, uPCR ≥150mg/g was found to have a stronger association with hepatic fibrosis than
uACR ≥30mg/g (adjusted odds ratio 1.55 [95% CI 1.03–2.33] vs adjusted odds ratio 1.16 [95% CI, 0.72–1.87]).
In conclusion, patients with iNAP and albuminuria had a higher prevalence of hepatic fibrosis than those without proteinuria. Total
proteinuria was associated with advanced liver fibrosis, whereas albuminuria was related to hepatic steatosis.
Abbreviations: AHA = American Heart Association, BMI = body mass index, CKD = chronic kidney disease, DKD = diabetic
kidney disease, eGFR = estimated glomerular filtration rate, FIB-4 = Fibrosis-4 calculator, HbA1c = hemoglobin A1c, HOMA-IR =
homeostasis model assessment of insulin resistance, iNAP = isolated non-albumin proteinuria, NAFLD = non-alcoholic fatty liver
disease, NAP = non-albumin proteinuria, NFS = non-alcoholic fatty liver disease fibrosis score, NHLBI = National Heart, Lung, and
Blood Institute, NLFS = non-alcoholic fatty liver disease liver fat score, NP = non-proteinuria, uACR = urinary albumin-to-creatinine
ratio, uPCR = urinary protein-to-creatinine ratio.
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With the dramatically increased prevalence and incidence of non-
alcoholic fatty liver disease (NAFLD) worldwide, this condition
has had a great impact on the development of hepatic fibrosis,
cirrhosis, and ultimately hepatocellular carcinoma.[1] The
prevalence of NAFLD in Asia was reported to be ∼45%, which
is similar to the global NAFLD prevalence.[2,3] In patients with
type 2 diabetes mellitus (T2D), the NAFLD prevalence rate
explosively increases, reportedly from 50% to 70%.[4] In
addition, NAFLD is known to precede the development of
T2D and is now considered a risk factor of T2D.[5] NAFLD and
T2D share a common denominator: hepatic and peripheral
insulin resistance. The NAFLD state is characterized by
inappropriately decreasing hepatic gluconeogenesis suppression
and glycogen synthesis, and increasing hepatic lipid accumula-
tion.[6] Considering the crucial role of the liver in the
pathophysiology of T2D, the association between NAFLD and
T2D is inevitable. Additionally, there is convincing evidence that
patients with T2D and NAFLD experience aggravation of
diabetic complications including cardiovascular disease and
nephropathy.[4,7]
Diabetic kidney disease (DKD), one of the chief complications
of T2D, affects about 40% of patients with T2D and is a major
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albuminuria reflects impairment of the glomerulus and is altered
by blood pressure and other cardiovascular risk factors, it is a
well-known marker and a diagnostic criterion for DKD.[9] These
aspects of albuminuria not only could be confounding factors in
investigating the association between cardiovascular risk factors,
but can also impose several limitations in estimating the risk of
DKD progression in the early stages of the disease.[10]
Proteinuria, which also includes non-albumin proteinuria
(NAP), can be a more sensitive screening marker than
albuminuria for predicting chronic kidney disease (CKD)
progression.[11] Further, measurement of total proteinuria or
urinary albumin-to-total urinary protein ratio, which also reflects
a tubulointerstitial pathology of the kidney, is gaining popularity
as an index of diabetic complications.[12]
Recent studies have reported the possibility that the presence of
NAFLD affects DKD.[7] An observational study conducted on
2103 participants with T2D and NAFLD demonstrated that the
risk for CKD was 1.87-fold increased compared with those who
did not have evidence of NAFLD.[13] However, a pooled
systematic meta-analysis study demonstrated the insignificant
association between albuminuria and NAFLD among patients
with diabetes, whereas the risk of albuminuria was 1.67-fold
increased in patients with NAFLD compared with individuals
without NAFLD in the general population.[14]
In this regard, the associations between NAFLD (either hepatic
steatosis or fibrosis) and DKD (assessed using either albuminuria
or proteinuria) remain inconsistently reported. The aim of this
study was to investigate the association between hepatic steatosis
or fibrosis and the status of proteinuria in Korean patients with
T2Dwho underwent concurrent evaluations for albuminuria and
total proteinuria.2. Methods
2.1. Study population
This is a retrospective study and we reviewed patient data using
electronic medical records. We enrolled patients aged ≥19 years
with T2D and previously diagnosed fatty liver disease confirmed
by ultrasound or computerized tomography from July 2015 to
December 2018 at Severance Hospital (a tertiary university
hospital in Seoul, Korea). T2D was defined according to the
International Classification of Diseases, 10th revision. Patients
were excluded if they fulfilled any one of the following criteria:
age <19 years, type 1 diabetes, pregnancy, hepatic diseases other
than NAFLD, renal diseases other than DKD, renal replacement
therapy including renal transplantation and dialysis, or alcohol
consumption >210g/wk for men and 140g/wk for women. Age,
sex, weight, height, waist circumference, blood pressure,
duration of diabetes, and current medications were recorded.
Body mass index (BMI) was calculated as body weight divided by
height squared (kg/m2). The diagnosis of metabolic syndrome
followed the definition of the AmericanHeart Association (AHA)
and the National Heart, Lung, and Blood Institute (NHLBI)
statements for Asian populations in 2005.[15] Hypertension was
defined as a systolic blood pressure of ≥130mmHg and/or a
diastolic blood pressure of ≥85mmHg, or current use of
antihypertensive medications according to the AHA/NHLBI
scientific statement. NAFLD was defined using a previously
validated fatty liver prediction model (≥0.64 the NAFLD liver fat
score [NLFS]).[16] The Fibrosis-4 calculator (FIB-4 index)[17] and2
NAFLD fibrosis score (NFS)[18] were assessed to estimate the
hepatic fibrosis burden, and significant fibrosis was defined as
either FIB-4 ≥2.67 or NFS ≥0.676, as previously ascertained.
The study protocol received ethical approval from the
institutional review board at the Yonsei University College of
Medicine (No. 4–2019-0317), which waived the need for
informed consent because the database was only retrospectively
accessed for analytical purposes and personal information was
not used.2.2. Measurements of blood and urinary parameters
Following an overnight fast (≥8hours), morning spot urine
sample for measuring urinary albumin, protein, and creatinine, as
well as blood samples for measuring complete blood count,
chemistry profiles, insulin/C-peptide, and glucose parameters
including hemoglobin A1c (HbA1c) and glycated albumin were
collected before (0minute; designated as basal) and after (90
minutes; designated as stimulated) the ingestion of a standardized
mixed meal. Insulin sensitivity was assessed using the homeosta-
sis model assessment of insulin resistance, HOMA-IR= [(basal
insulin [pM]glucose [mM])/156.3].[19] The estimated glomer-
ular filtration rate was derived from the CKD Epidemiology
Collaboration creatinine-based equation.[20]
Urinary albumin and protein levels were expressed as urinary
albumin-to-creatinine ratio (uACR) and urinary protein-to-
creatinine ratio (uPCR), respectively, to minimize the influence
of variations in kidney function. We defined proteinuria as uPCR
≥150mg/g, according to the most conservative reported normal
value for urinary protein excretion of <150mg/d.[21] Albumin-
uria was defined as uACR ≥30mg/g, according to the Kidney
Disease: Improving Global Outcomes recommendation.[22] NAP
was indirectly calculated from the difference between uPCR and
uACR using the following formula: NAP (mg/g)=uPCR (mg/g)–
uACR (mg/g).[23] iNAP and non-proteinuria (NP) were defined as
both uPCR of ≥150mg/g and uACR of <30mg/g,[24] and both
uPCR of <150mg/g and uACR of <30mg/g, respectively.2.3. Statistical analysis
Data were presented as mean± standard deviation for normally
distributed continuous variables, median (interquartile range) for
non-normally distributed continuous variables, and number
(percentage) for categorical variables. Statistical analyses were
performed using IBM SPSS statistical software for Windows,
version 23.0 (IBM, Armonk, NY). We analyzed the participants’
characteristics according to the status of proteinuria, using one-
way analysis of variance (ANOVA) or Kruskal-Wallis test for
comparing continuous variables and the chi-square test for
comparing categorical variables, followed by post-hoc analyses
using the Bonferroni procedure for ANOVA andDunn procedure
for the Kruskal-Wallis test. To demonstrate the association
between the degrees of albuminuria and proteinuria and hepatic
steatosis or fibrosis, we categorized the values of those markers
into tertiles. Correlations between urinary markers (uACR,
uPCR) and indices of hepatic steatosis/fibrosis were analyzed
using Spearman correlation coefficients. Multiple logistic regres-
sion analysis was applied to determine the independent
association between urinary indices and hepatic parameters.
Several related factors were calibrated in various adjusted
models. Adjusted ORs (aORs) and 95% CIs were determined.
A P-value of <.05 was considered statistically significant.
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3.1. Clinical characteristics of patients according
to urinary protein–creatinine ratio and urinary
albumin–creatinine ratio
In this study, we enrolled 1108 patients with T2D (641 men and
467 women) who had undergone both urine tests for uACR and
uPCR measurements and biochemical evaluations for the
calculation of hepatic steatosis and fibrosis indices. The mean
patient age and median duration of T2Dwere 59.6 and 1.0 years,
respectively. On the basis of the definitions provided in the
Methods section, we classified the patients into NP (708
[63.9%]), isolated NAP (iNAP) (91 [8.2%]), and albuminuria
(309 [27.9%]) groups (Table 1). Among these 3 groups, there
were no differences in BMI, waist circumference, systolic blood
pressure, and hepatic enzymes. However, the iNAP group
showed a higher proportion of female patients, a longer duration
of T2D, a higher blood glucose level, and decreased kidney
function (all P< .05) compared with the NP group. The
albuminuria group also showed a longer duration of T2D,
decreased kidney function, and increased HOMA-IR values with
poor glycemic control. The proportion of patients with
hypertension and metabolic syndrome was increased in both
the iNAP and albuminuria groups.
3.2. Correlation between urinary markers and hepatic
steatosis/fibrosis indices
As shown in Table 2, no significant difference in hepatic steatosis
according to NLFS was found among the NP, iNAP, and
albuminuria groups. With respect to hepatic fibrosis, both the
iNAP and albuminuria groups showed significantly increasedTable 1
Baseline clinical characteristics of patients.
Total (N=1108) Non-proteinuria (n=708)
Age, y 58.5±13.0
Female sex, n (%) 306 (43.2)
BMI, kg/m2 25.8±3.7
WC, cm 89.5±9.5
Systolic BP, mmHg 129.2±65.6
Diastolic BP, mmHg 78.9±11.0
Duration of diabetes, y 1.0 (0–6.0)
Glucose, fasting, mg/dL 139.5±43.0
Glucose, stimulated, mg/dL 191.0±65.3
HbA1c, % 7.3±1.7
HOMA-IR 2.9 (1.7–4.7)
Urinary ACR (mg/g creatinine) 8.2±7.0
Urinary PCR (mg/g creatinine) 87.3±25.4




Hypertension, n (%) 468 (66.1)
Metabolic syndrome, n (%) 496 (70.1)
Data are expressed as mean± standard deviation for normally distributed continuous variables, median (
variables.
ACR= albumin-to-creatinine ratio, ALT= alanine aminotransferase, AST= aspartate aminotransferase,
Collaboration, eGFR= estimated glomerular filtration rate, HbA1c=hemoglobin A1c, HOMA-IR=homeosta
creatinine ratio, WC=waist circumference.
∗
P< .05 versus non-proteinuria, by post-hoc analyses (Bonferroni test).
† P< .05 versus isolated NAP, by post-hoc analyses (Bonferroni test).
‡ Significant in chi-square test, P< .05.
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NFS (all P< .05). Another index of hepatic fibrosis, the FIB-4
index, was increased in the iNAP and albuminuria groups,
without statistical significance. As the iNAP and albuminuria
groups showed higher NFS, we further analyzed the association
between urine indices and hepatic steatosis. uACR was positively
correlated with the NLFS (Spearman correlation, r=0.087,
P= .004) (Table 3), whereas uPCR was not significantly
correlated with the index of hepatic steatosis (Spearman
correlation, r=0.001, P= .980). However, both uACR and
uPCR were positively correlated with the indices of hepatic
fibrosis (uACR: r=0.076, P= .012 for FIB-4 index and r=0.064,
P= .033 for NFS; uPCR: r=0.111, P< .001 for FIB-4 index and
r=0.123, P< .001 for NFS). In addition, uPCR showed a
stronger linear correlation with the indices of hepatic fibrosis
than uACR.
When urinary indices (uACR, uPCR) and the hepatic steatotic
and fibrotic burden were stratified by tertiles, uACR showed a
significantly positive relationship with the steatosis index
(P= .016) (Fig. 1A–C). In contrast to uACR, there was no
significant relationship between uPCR tertiles and the steatosis
index (Fig. 1D–F). uPCR showed a strong positive relationship
with the 2 fibrosis indices (FIB-4 index and NFS, both P< .05).
3.3. Risk of hepatic steatosis/fibrosis according to urinary
protein–creatinine ratio and urinary albumin–creatinine
ratio
To further determine the relationship between NAFLD and
urinary markers, logistic regression was performed in which
potential confounders were controlled for in a stepwise manner
(Table 4). The association between liver steatosis and uACR was












































62 (68.1) 259 (83.8) <.001‡
67 (73.6) 252 (81.6) .001‡
interquartile range) for non-normally distributed continuous variables, and number (%) for categorical
BMI=body mass index, BP=blood pressure, CKD-EPI=Chronic Kidney Disease Epidemiology
tic model assessment of insulin resistance, NAP=non-albumin proteinuria, uPCR=urinary protein-to-
Table 3
Relationship between hepatic steatosis/fibrosis indices and
uACR/uPCR.
r (uACR) P-value r (uPCR) P-value
Index of liver steatosis
NLFS 0.087 .004 0.001 .980
Index of liver fibrosis
FIB-4 index 0.076 .012 0.111 <.001
NFS 0.064 .033 0.123 <.001
FIB-4 = Fibrosis-4, NFS = non-alcoholic fatty liver disease fibrosis score, NLFS = non-alcoholic fatty
liver disease liver fat score, uACR = urinary albumin-to-creatinine ratio, uPCR = urinary protein-to-
creatinine ratio.
NOTE. Bold indicates P< .05.
Figure 1. Association of NAFLD and hepatic fibrosis according to urinary marker t
tertiles and the association of uPCR with (D) NLFS, (E) FIB-4 index, and (F) NFS b
group. FIB-4=Fibrosis-4, NFS=non-alcoholic fatty liver disease fibrosis score, NL
creatinine ratio, uPCR=urinary protein-to-creatinine ratio.
Table 2
Comparison of hepatic steatosis and fibrosis indices according to proteinuria status.
No proteinuria (n=708) Isolated NAP (n=91) Albuminuria (n=309) P-value
Index of liver steatosis
NLFS 0.22 (1.89) 0.02 (1.83) 0.39 (1.84) .089
NLFS>–0.64, n (%) 528/708 (74.6%) 64/91 (70.3%) 247/309 (79.9%) .085
Index of liver fibrosis
FIB-4 index 1.13 (0.78) 1.18 (1.11) 1.27 (0.88) .061
FIB-4 index ≥2.67, n (%) 38/704 (5.4%) 9/90 (10.0%) 27/305 (8.9%) .058
NFS 0.87 (1.59) 0.61 (1.87) 0.56 (1.65) .003
NFS ≥0.676, n (%) 67/708 (9.5%) 17/91 (18.7%) 51/309 (16.5%) .001
Data are expressed as median (interquartile range) for continuous variables and number (%) for categorical variables.
FIB-4= Fibrosis-4, NAP=non-albumin proteinuria, NFS=non-alcoholic fatty liver disease fibrosis score, NLFS=non-alcoholic fatty liver disease liver fat score.
NOTE. Bold indicates P< .05.
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95% CI 1.14–2.35; P= .007), HOMA-IR, HbA1c, and duration
of T2D (model 3: OR 1.56; 95% CI 1.01–2.40; P= .044). The
association became insignificant after further adjustments. A
similar pattern was also observed in the association between liver
fibrosis and uACR.
For uPCR, there was an insignificant association of hepatic
steatosis after adjustment. However, liver fibrosis showed a
significant association with uPCR and the association remained
significant after adjusting for age, sex (model 1: OR 1.57; 95%CI
1.08–2.30; P= .019), BMI (model 2: OR 1.63; 95% CI 1.11–
2.40; P= .013), HOMA-IR, HbA1c, duration of T2D (model 3:
OR 1.55; 95% CI 1.03–2.33; P= .036), hypertension, alanine
aminotransferase, and total cholesterol (model 4: OR 1.55; 95%
CI 1.03–2.33; P= .038).ertiles. The association of uACR with (A) NLFS, (B) FIB-4 index, and (C) NFS by
y tertiles. T1 for lowest tertile and T2 for middle tertile, and T3 for highest tertile
FS=non-alcoholic fatty liver disease liver fat score, uACR=urinary albumin-to-
Table 4
Odds ratios for the presence of hepatic steatosis or fibrosis according to urinary ACR and urinary PCR.
Hepatic steatosis according to NLFS Hepatic fibrosis according to NFS
aOR (95% CI) P-value aOR (95% CI) P-value
Albuminuria (uACR ≥30mg/g)
Model 1 1.37 (0.99–1.89) .056 1.53 (1.03–2.26) .034
Model 2 1.64 (1.14–2.35) .007 1.53 (1.02–2.27) .038
Model 3 1.56 (1.01–2.40) .044 1.45 (0.96–2.19) .081
Model 4 1.18 (0.72–1.94) .520 1.49 (0.98–2.26) .063
Proteinuria (uPCR ≥150mg/g)
Model 1 1.20 (0.89–1.62) .243 1.57 (1.08–2.30) .019
Model 2 1.60 (1.14–2.24) .007 1.63 (1.11–2.40) .013
Model 3 1.36 (0.90–2.05) .147 1.55 (1.03–2.33) .036
Model 4 1.16 (0.72–1.87) .543 1.55 (1.03–2.33) .038
Model 1 adjusted for age (applied as a categorical variable with a median cutoff value of 60 years) and sex. Model 2 adjusted for model 1 parameters plus body mass index. Model 3 adjusted for model 2
parameters plus HOMA-IR, hemoglobin A1c, and duration of diabetes. Model 4 adjusted for model 3 parameters plus hypertension, alanine aminotransferase, and total cholesterol.
aOR= adjusted odds ratio, CI= confidence interval, NFS=non-alcoholic fatty liver disease fibrosis score, NLFS=non-alcoholic fatty liver disease liver fat score, uACR=urinary albumin-to-creatinine ratio,
uPCR=urinary protein-to-creatinine ratio.
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Recent studies have reported the possibility that the presence of
NAFLD affects DKD.[7] However, the relationship between
NAFLD and DKD has remained controversial. In addition, the
pathophysiologic mechanisms between albuminuria and NAFLD
have not been clearly demonstrated and are questionable. In
urine, the total protein amount is primarily accounted for by
albumin, although other pathophysiological proteins and non-
albumin proteins are also present. As the presence of albuminuria
suggests glomerular damage, NAP could indicate kidney injury of
a tubular origin.[25] Accordingly, we hypothesized that the
development and progression of fibrosis in the hepatic paren-
chyma in T2D might simultaneously occur in the kidney,
especially in the renal tubules. In this study, we observed the
correlation between proteinuria and the pathological status of the
liver. The current study elucidated 2 main findings. First, the
presence of albuminuria in patients with T2D was closely related
to hepatic steatosis. Second, total proteinuria, which reflects
injury of both glomeruli and proximal tubules, was more closely
associated with hepatic fibrosis progression. This association
remained significant after adjusting for other essential factors.
With respect to albuminuria and NAFLD, one cross-sectional
study of 1763 patients with T2D and NAFLD ascertained using
transient elastography (FibroScan) demonstrated that the risk of
albuminuria in persons with diabetes and hepatic fibrosis was
1.53-fold higher than in those without fibrosis.[26] Furthermore,
the risk of albuminuria increased with greater severity of liver
fibrosis. In our study, the uACR value was significantly more
associated with the degree of hepatic steatosis ascertained using
the NLFS (r=0.087, P= .004) than with the degree of hepatic
fibrosis assessed using FIB-4 (r=0.076, P= .012) and NFS (r=
0.064, P= .033). However, uPCR was associated only with the
degree of hepatic fibrosis. Because albuminuria is known to be
related to insulin resistance, which is the underlying mechanism
of metabolic syndrome and other cardiometabolic disease,[27,28]
and insulin resistance also plays a role in the development of
hepatic steatosis,[29,30] the link between albuminuria and hepatic
steatosis in this study is acceptable and reasonable.
With respect to the association between proteinuria and
hepatic fibrosis, patients with iNAP showed a higher prevalence
of hepatic fibrosis and more advanced stages of liver fibrosis
than those with albuminuria and NP. The hepatic fibrosis indices5
(FIB-4 and NFS) were more closely associated with uPCR
(P< .001 for both) than with uACR (P= .980). In addition, this
association remained after the application of various modalities
for assessing hepatic fibrosis. Moreover, multiple logistic
regression analysis showed a significant association between
hepatic fibrosis and proteinuria. It has been known that iNAP is
related to tubulointerstitial pathologies and that low urinary
albumin-to-total protein ratio is strongly associated with
tubulointerstitial disease in renal biopsies.[12] Previously, we
demonstrated that uncontrolled hyperglycemia along with a
lower HOMA-b, reflecting oxidative stress to the whole body
system, affects renal tubulopathy in early DKD.[31] Liver fibrosis
is driven by necroinflammation in response to parenchymal
injury.[32] A widely accepted two-hit theory explaining the
progression to hepatic fibrosis involves triglyceride deposition in
hepatocytes followed by formation of reactive oxygen species and
free radicals.[33] These conditions activate proinflammatory
cytokines and induce oxidative stress, consequently leading to
fibrosis.[33] Considering the contribution of uncontrolled hyper-
glycemia to chronic inflammation as well as the correlation of
NAP to hyperglycemia, we postulate that NAP, which is a
specialized portion of the total proteinuria, might more precisely
reflect hepatic fibrosis compared with albuminuria.
With respect to the clinical and pathophysiological features of
iNAP defined as both uPCR ≥150mg/g and uACR <30mg/g,[24]
the prevalence of iNAP has been reported to be >10% among
patients with T2D.[34,35] A comparable result was observed in
our study. Similar to the previous study,[35] the comparatively less
metabolic burden of the iNAP group, such as the presence of
hypertension and metabolic syndrome, than that of the
albuminuria group was also observed in the current study.[25]
Although the increase in hepatic steatosis in patients with T2D
with iNAP was not clear, these patients showed fibrosis
progression as assessed using FIB-4 and NFS. The pathophysio-
logical mechanisms that result in NAP are multifactorial and not
fully understood. The physiological changes that induceNAP and
whether NAP plays a pathophysiological role in hepatic fibrosis
remain unclear. However, as mentioned above, insulin resistance
or systemic inflammation can also lead to both conditions.
Increased glucose reabsorption due to hyperglycemia in the
proximal tubule could cause tubulointerstitial hypoxia and
increased oxidative stress.[36,37] Chronic hyperglycemia per se
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ly, the association between renal tubule function and hepatic
fibrosis may be explained by hepatorenal syndrome. In
hepatorenal syndrome, hemodynamic stress activates the renin-
angiotensin aldosterone system, and consequently, acute tubular
necrosis (the most common cause of acute kidney injury in
cirrhosis) occurs.[39] Although a detailed mechanism for the
independent association between the degree of NAP and fibrotic
burden in the liver was not demonstrated in our cross-sectional
study, our results were rather consistent with those of previous
studies proposing NAP as a marker for future T2D complications
including hepatic fibrosis.[25,40] In this regard, if the presence of
albuminuria is to be applied only as a screening or monitoring
marker for the identification of diabetes nephropathy, the risk of
hepatic fibrosis progression in patients with proteinuria without
albuminuria could possibly be neglected.
The current study has a few limitations. First, owing to the
retrospective design of this study, we could not elucidate the causal
relationship between the observed findings. Selection bias could be
present because we enrolled only patients who underwent all
related evaluations. In addition, this study was based on the one
tertiary university hospital’s medical record, our results could not
reflect the entire Korean population. Further multi-centered,
longitudinal study would show more clear association between
liver status and albuminuria. Second, uPCR and uACR were
measured once in most cases, and single rather than repeated
measurements could have a low positive predictive value for the
detection and segregation of the iNAP group.[24] Third, despite the
acceptance of fatty liver prediction models including the NLFS,
FIB-4, and NFS as indices for detecting NAFLD, these models are
not currently gold standard methods for detecting NAFLD. Liver
biopsy is regarded for precise diagnostic tool for evaluating the
fatty liver disease, however, due to its complication, non-invasive
diagnostic tools including NLFS has been widely utilized.[16]
Fourth, the number of patients in the NAP group was too small to
fully interpret the clinical andpathophysiological relevanceofNAP
with respect to hepatic steatosis and fibrosis in T2D.
In conclusion, our results showed that patients with T2D
frequently have NAP and patients with NAP/albuminuria were
associated with a higher risk for significant hepatic fibrosis.
Additionally, the level of uPCR was associated with an increased
hepatic fibrosis score, whereas uACRwas associated with hepatic
steatosis score. The current study may contribute to the
understanding of the hepatic complications in patients with
T2D. The identification of NAP as well as conventional DKD
markers, such as uACR and uPCR, may help predict future
hepatic complications in T2D. Further studies in larger numbers
of patients with longer periods of observation with liver biopsy
are needed tomore clearly determine the associations between the
proteinuria status and the progression of NAFLD.Acknowledgments
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